GEN-MKT-18-7897-A
Oct 29, 2024 | Blogs, Echo® MS+ system, Pharma, QTRAP / Triple Quad, ZenoTOF 7600 system | 0 comments
Read time: 2 minutes
Drug development is a challenging process that requires diverse analytical solutions and the expertise of research scientists.
Within drug discovery confident go/no-go decisions need to be made as quickly as possible. Often, highly sensitive techniques are needed to accurately monitor concentrations of biomarkers, therapeutic candidates, and their metabolites. QA/QC laboratories need consistent performance everyday over many years.
We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.
The guide covers bio/pharmaceutical quantitative assays from discovery to QA/QC, for large and small molecules. Discussing challenges regularly faced by scientists, along with potential solutions.
Download the guide >
The guide includes comprehensive chapters addressing multiple challenges and solutions regularly faced in drug development.
Discovery
Development (Small and large molecules)
Regulatory solutions
QA/QC and lot release
Products
Download the guide here >
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network